CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial Can the Vanishing Stent Reappear? Fix the Technique, or Fix the Device? Healthy Behavior, Risk Factor Control, and Survival in the COURAGE Trial Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial Disrupting Fellow Education Through Group Texting: WhatsApp in Fellow Education? Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Coronary Angiography after Cardiac Arrest — The Right Timing or the Right Patients? Mitral Valve Remodeling and Strain in Secondary Mitral Regurgitation: Comparison With Primary Regurgitation and Normal Valves 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society Qualitative and Mixed Methods Provide Unique Contributions to Outcomes Research
|<<... 65 66 67 68 69 70 71 ...>>|

Clinical Trial2018 Oct 27. [Epub ahead of print]

JOURNAL：J Am Coll Cardiol. Article Link

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial

M Szarek, HD White, PH Steg, ODYSSEY OUTCOMES Committees and Investigators. Keywords: Alirocumab; acute coronary syndrome; total events

FuLL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top